--- title: "Relay Therapeutics (RLAY) news: offering and lawsuit" url: "https://aibio.space/companies/relay-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "RLAY offering and lawsuit news: Relay Therapeutics adds $212,978,049 to at-the-market stock program. Relay Therapeutics, Inc. (NASDAQ: RLAY), United States." --- RLAY Relay Therapeutics, Inc. NASDAQ · United States # Relay Therapeutics (RLAY) news RLAY offering and lawsuit news Legal · 2026-08-06 ## [Relay Therapeutics is nominal defendant in Delaware derivative suit over 2021 to 2023 board pay](https://aibio.space/news/relay-therapeutics-nominal-defendant-delaware-derivative-suit-2021/) Hayes v. Borisy, filed December 2024, names Borisy and other directors and officers of Relay (Nasdaq: RLAY) that the 10-Q does not list. The case is in discovery and Relay cannot predict the outcome or any loss. ## Latest Relay Therapeutics news 1. 2026-08-06 Financings [Relay Therapeutics adds $212,978,049 to at-the-market stock program](https://aibio.space/news/relay-therapeutics-adds-212-978-049-market-stock-program/) Relay Therapeutics amended its stock sales agreement on August 6, 2026 to add $212,978,049 of at-the-market sales, raising the program to $462,978,049. The prospectus puts immediate dilution at $14.22 a share for investors who buy in the offering. 2. 2026-06-09 Listings [Relay Therapeutics holders approve raising authorized shares to 450,000,000](https://aibio.space/news/relay-therapeutics-holders-approve-raising-authorized-shares-450-000/) Common stock authorized rises from 300,000,000 shares. Relay filed the amendment in Delaware on June 9, 2026. 3. 2025-06-04 Distress [Relay Therapeutics agrees to end Binney Street lease early and move to smaller space](https://aibio.space/news/relay-therapeutics-agrees-end-binney-street-lease-early-move-smaller/) Relay paid a lease modification payment of approximately $2.5 million and a relocation payment of approximately $3.5 million. It says the changes cut rent expense by approximately $16 million. ## Relay Therapeutics at a glance - **Ticker**: RLAY - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $121.2 million ### Related companies - [Spruce Biosciences](https://aibio.space/companies/spruce-biosciences/) NASDAQ: SPRB - [Armata Pharmaceuticals](https://aibio.space/companies/armata-pharmaceuticals/) AMEX: ARMP - [City Therapeutics](https://aibio.space/companies/city-therapeutics/) NASDAQ: CTY - [Greenwich LifeSciences](https://aibio.space/companies/greenwich-lifesciences/) NASDAQ: GLSI - [Septerna](https://aibio.space/companies/septerna/) NASDAQ: SEPN - [Humacyte](https://aibio.space/companies/humacyte/) NASDAQ: HUMA - [Inhibrx Biosciences](https://aibio.space/companies/inhibrx-biosciences/) NASDAQ: INBX - [Ensysce Biosciences](https://aibio.space/companies/ensysce-biosciences/) NASDAQ: ENSC ### Also on NASDAQ - [CASTLE BIOSCIENCES INC](https://aibio.space/companies/castle-biosciences/) CSTL - [Autolus Therapeutics](https://aibio.space/companies/autolus-therapeutics/) AUTL - [Tenon Medical](https://aibio.space/companies/tenon-medical/) TNON - [Bicycle Therapeutics](https://aibio.space/companies/bicycle-therapeutics/) BCYC - [FibroBiologics](https://aibio.space/companies/fibrobiologics/) FBLG - [BioCardia](https://aibio.space/companies/biocardia/) BCDA ## Relay Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$15.4 million](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/) | [$10.0 million](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/) | | Net income (loss) | [-$276.5 million](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/) | [-$337.7 million](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/) | | Cash from operations | [-$235.5 million](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/) | [-$249.1 million](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/) | | Cash and equivalents | [$84.0 million](https://www.sec.gov/Archives/edgar/data/1812364/000119312526338056/) | [$124.3 million](https://www.sec.gov/Archives/edgar/data/1812364/000119312526076739/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $121.2 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Relay Therapeutics Has Relay Therapeutics raised money recently? Our latest story on this, dated Aug 6, 2026: "Relay Therapeutics adds $212,978,049 to at-the-market stock program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/relay-therapeutics-adds-212-978-049-market-stock-program/). Is Relay Therapeutics involved in a lawsuit? Our latest story on this, dated Aug 6, 2026: "Relay Therapeutics is nominal defendant in Delaware derivative suit over 2021 to 2023 board pay". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/relay-therapeutics-nominal-defendant-delaware-derivative-suit-2021/). What is the ticker symbol of Relay Therapeutics? Relay Therapeutics, Inc. trades under the ticker RLAY on NASDAQ. Where is Relay Therapeutics listed? Relay Therapeutics, Inc. is listed on NASDAQ. What is the SEC CIK of Relay Therapeutics? The SEC Central Index Key (CIK) for Relay Therapeutics, Inc. is 1812364. Its filings are on SEC EDGAR. How many shares does Relay Therapeutics have outstanding? 219,141,631 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-06. Which country or territory is Relay Therapeutics listed under? Our directory records Relay Therapeutics, Inc. under United States. What does Relay Therapeutics do? Our directory classifies Relay Therapeutics, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Relay Therapeutics? The ISIN recorded for Relay Therapeutics, Inc. is US75943R1023. Does aibio.space cover Relay Therapeutics? aibio.space lists Relay Therapeutics, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Relay Therapeutics incorporated? SEC records list its state or country of incorporation as DE. What was Relay Therapeutics's revenue last year? $15.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Relay Therapeutics profitable? Relay Therapeutics, Inc. reported a net loss of $276.5 million for the fiscal year ended Dec 31, 2025, and used $235.5 million of cash in operations, per its annual report to the SEC. How much cash does Relay Therapeutics have? $121.2 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Relay Therapeutics (RLAY) stock news? Our latest story on Relay Therapeutics, dated Aug 6, 2026: "Relay Therapeutics is nominal defendant in Delaware derivative suit over 2021 to 2023 board pay". Hayes v. Borisy, filed December 2024, names Borisy and other directors and officers of Relay (Nasdaq: RLAY) that the 10-Q does not list. The case is in discovery and Relay cannot predict the outcome or any loss. [Source](https://aibio.space/news/relay-therapeutics-nominal-defendant-delaware-derivative-suit-2021/). ## Investor discussion: Relay Therapeutics Members talk about Relay Therapeutics (RLAY). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Relay Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-08-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1812364/000119312526338013/rlay-ex99_1.htm) 2. 2026-06-09 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1812364/000119312526263873/rlay-20260609.htm) 3. 2026-05-19 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1812364/000119312526231113/d139941d424b5.htm) 4. 2025-06-11 Distress Reported a leadership departure tied to a disagreement or a restructuring. SEC Form 8-K (Items 5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1812364/000119312525139146/d948938dex991.htm) 5. 2025-06-04 Distress Reported the end of a material agreement. SEC Form 8-K (Items 1.01,1.02). [Source](https://www.sec.gov/Archives/edgar/data/1812364/000119312525134908/d48650d8k.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:RLAY on TradingView](https://www.tradingview.com/symbols/NASDAQ-RLAY/). ## SEC filings and registration - **SEC name**: Relay Therapeutics, Inc. - **CIK**: 1812364 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: RLAY (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Large accelerated filer - **Business address**: 60 HAMPSHIRE STREET, CAMBRIDGE, MA, 02139 - **Phone**: 617-370-8837 - **Shares outstanding**: 219,141,631 as of 2026-07-31 (10-Q filed 2026-08-06) ### Recent filings (8-K and 6-K are the company's own announcements) - [424B5](https://www.sec.gov/Archives/edgar/data/1812364/000119312526338292/d151325d424b5.htm) filed 2026-08-06 - [10-Q](https://www.sec.gov/Archives/edgar/data/1812364/000119312526338056/rlay-20260630.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1812364/000119312526338013/rlay-20260806.htm) filed 2026-08-06 - [8-K](https://www.sec.gov/Archives/edgar/data/1812364/000119312526263873/rlay-20260609.htm) filed 2026-06-09 - [8-K](https://www.sec.gov/Archives/edgar/data/1812364/000119312526234862/d128795d8k.htm) filed 2026-05-21 - [424B5](https://www.sec.gov/Archives/edgar/data/1812364/000119312526234428/d139941d424b5.htm) filed 2026-05-21 - [424B5](https://www.sec.gov/Archives/edgar/data/1812364/000119312526231113/d139941d424b5.htm) filed 2026-05-19 - [8-K](https://www.sec.gov/Archives/edgar/data/1812364/000119312526229770/rlay-20260519.htm) filed 2026-05-19 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001812364), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Relay Therapeutics, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker RLAY, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Relay Therapeutics, Inc. - **Ticker**: RLAY - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US75943R1023 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-RLAY/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/relay-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Relay Therapeutics (RLAY) news: offering and lawsuit", 2026-10-31, https://aibio.space/companies/relay-therapeutics/